Literature DB >> 9686386

Use of body surface area (BSA)-based dosages to calculate chemotherapeutic drug dose in dogs: I. Potential problems with current BSA formulae.

G S Price1, D L Frazier.   

Abstract

The dose of most cancer chemotherapeutic drugs administered to dogs is calculated on the basis of estimated body surface area (BSA); however results of some chemotherapy trials have revealed that this dosing method increases toxicosis in small dogs. The current formula used to estimate BSA in dogs may be inaccurate or the assumption that BSA correlates with chemotherapeutic drug exposure may be unfounded. Results presented in this review suggest that canine BSA estimates may be inaccurate because the values for the constant (K) and exponent (a) in the formulae (BSA = K.Wa) are incorrect or because a linear parameter such as body length is lacking from the formulae. Results that suggest the relationship between BSA and the physiologic/pharmacologic factors that influence drug exposure may not be closely correlated are also presented. Studies are warranted to determine whether there are dosing methods that normalize chemotherapeutic drug toxicity in dogs.

Entities:  

Mesh:

Year:  1998        PMID: 9686386     DOI: 10.1111/j.1939-1676.1998.tb02121.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  20 in total

1.  A computer program for calculation of doses and prices of injectable medications based on body weight or body surface area.

Authors:  T D Ambrisko; T Nemeth
Journal:  Can J Vet Res       Date:  2004-01       Impact factor: 1.310

2.  Development of a limited-sampling model for prediction of doxorubicin exposure in dogs.

Authors:  L A Wittenburg; D H Thamm; D L Gustafson
Journal:  Vet Comp Oncol       Date:  2012-07-03       Impact factor: 2.613

Review 3.  Species differences in tumour responses to cancer chemotherapy.

Authors:  Jessica Lawrence; David Cameron; David Argyle
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-07-19       Impact factor: 6.237

4.  Increased risk of select glucocorticoid adverse events in dogs of higher body weight.

Authors:  Loren S Sri-Jayantha; Michael T Doornink; Bridget K Urie
Journal:  Can Vet J       Date:  2022-01       Impact factor: 1.008

5.  GLP-1(32-36)amide, a novel pentapeptide cleavage product of GLP-1, modulates whole body glucose metabolism in dogs.

Authors:  Dariush Elahi; Franca S Angeli; Amin Vakilipour; Olga D Carlson; Eva Tomas; Josephine M Egan; Joel F Habener; Richard P Shannon
Journal:  Peptides       Date:  2014-06-14       Impact factor: 3.750

6.  A unified formula for calculating body surface area of humans and animals.

Authors:  Jianfeng Wang; Eiji Hihara
Journal:  Eur J Appl Physiol       Date:  2004-03-11       Impact factor: 3.078

7.  Specific paucity of unmyelinated C-fibers in cutaneous peripheral nerves of the African naked-mole rat: comparative analysis using six species of Bathyergidae.

Authors:  Ewan St John Smith; Bettina Purfürst; Tamara Grigoryan; Thomas J Park; Nigel C Bennett; Gary R Lewin
Journal:  J Comp Neurol       Date:  2012-08-15       Impact factor: 3.215

8.  The normal electrocardiograms in the conscious newborn lambs in neonatal period and its progression.

Authors:  Karoline Koether; Carla Maria Vela Ulian; Maria Lucia Gomes Lourenço; Renato Souza Gonçalves; Mateus José Sudano; Raíssa Karolliny Salgueiro Cruz; Naiana da Silva Branchini; Angélica Alfonso; Simone Biagio Chiacchio
Journal:  BMC Physiol       Date:  2016-01-19

9.  Body surface area formulae: an alarming ambiguity.

Authors:  Grzegorz Redlarski; Aleksander Palkowski; Marek Krawczuk
Journal:  Sci Rep       Date:  2016-06-21       Impact factor: 4.379

10.  Vincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease.

Authors:  David N Phalen; Angela Frimberger; Stephen Pyecroft; Sarah Peck; Colette Harmsen; Suzanneth Lola; Beatriz de Mello Mattos; Kong M Li; Andrew J McLachlan; Antony Moore
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.